Cognition Therapeutics, Inc. (NASDAQ:CGTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Shares of Cognition Therapeutics, Inc. (NASDAQ:CGTX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are covering the stock, MarketBeat.com reports...